Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.8492 USD
−117.67 M USD
0.00 USD
35.55 M
About Athira Pharma, Inc.
Sector
Industry
CEO
Mark J. Litton
Website
Headquarters
Bothell
Founded
2011
FIGI
BBG00C77LX40
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ATHA is 0.6591 USD — it has decreased by −1.00% in the past 24 hours. Watch Athira Pharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Athira Pharma, Inc. stocks are traded under the ticker ATHA.
ATHA stock has fallen by −10.79% compared to the previous week, the month change is a 32.43% rise, over the last year Athira Pharma, Inc. has showed a −55.16% decrease.
We've gathered analysts' opinions on Athira Pharma, Inc. future price: according to them, ATHA price has a max estimate of 0.75 USD and a min estimate of 0.50 USD. Watch ATHA chart and read a more detailed Athira Pharma, Inc. stock forecast: see what analysts think of Athira Pharma, Inc. and suggest that you do with its stocks.
ATHA reached its all-time high on Dec 31, 2020 with the price of 34.7900 USD, and its all-time low was 0.4115 USD and was reached on Sep 26, 2024. View more price dynamics on ATHA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ATHA stock is 12.83% volatile and has beta coefficient of 3.14. Track Athira Pharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Athira Pharma, Inc. there?
Today Athira Pharma, Inc. has the market capitalization of 24.84 M, it has decreased by −10.02% over the last week.
Yes, you can track Athira Pharma, Inc. financials in yearly and quarterly reports right on TradingView.
Athira Pharma, Inc. is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
ATHA earnings for the last quarter are −0.75 USD per share, whereas the estimation was −0.70 USD resulting in a −6.89% surprise. The estimated earnings for the next quarter are −0.45 USD per share. See more details about Athira Pharma, Inc. earnings.
Athira Pharma, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ATHA net income for the last quarter is −28.74 M USD, while the quarter before that showed −26.86 M USD of net income which accounts for −7.01% change. Track more Athira Pharma, Inc. financial stats to get the full picture.
No, ATHA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 22, 2024, the company has 67.00 employees. See our rating of the largest employees — is Athira Pharma, Inc. on this list?
Like other stocks, ATHA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Athira Pharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Athira Pharma, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Athira Pharma, Inc. stock shows the sell signal. See more of Athira Pharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.